Literature DB >> 34042218

Local shifts in inflammatory and resolving lipid mediators in response to tendon overuse.

James F Markworth1,2, Kristoffer B Sugg2,3, Dylan C Sarver2,4, Krishna Rao Maddipati5, Susan V Brooks1,6.   

Abstract

Tendon inflammation has been implicated in both adaptive connective tissue remodeling and overuse-induced tendinopathy. Lipid mediators control both the initiation and resolution of inflammation, but their roles within tendon are largely unknown. Here, we profiled local shifts in intratendinous lipid mediators via liquid chromatography-tandem mass spectrometry in response to synergist ablation-induced plantaris tendon overuse. Sixty-four individual lipid mediators were detected in homogenates of plantaris tendons from ambulatory control rats. This included many bioactive metabolites of the cyclooxygenase (COX), lipoxygenase (LOX), and epoxygenase (CYP) pathways. Synergist ablation induced a robust inflammatory response at day 3 post-surgery characterized by epitenon infiltration of polymorphonuclear leukocytes and monocytes/macrophages (MΦ), heightened expression of inflammation-related genes, and increased intratendinous concentrations of the pro-inflammatory eicosanoids thromboxane B2 and prostaglandin E2 . By day 7, MΦ became the predominant myeloid cell type in tendon and there were further delayed increases in other COX metabolites including prostaglandins D2 , F2α , and I2 . Specialized pro-resolving mediators including protectin D1, resolvin D2 and D6, as well as related pathway markers of D-resolvins (17-hydroxy-docosahexaenoic acid), E-resolvins (18-hydroxy-eicosapentaenoic acid), and lipoxins (15-hydroxy-eicosatetraenoic acid) were also increased locally in response to tendon overuse, as were anti-inflammatory fatty acid epoxides of the CYP pathway (eg, epoxy-eicosatrienoic acids). Nevertheless, intratendinous prostaglandins remained markedly increased even following 28 days of tendon overuse together with a lingering MΦ presence. These data reveal a delayed and prolonged local inflammatory response to tendon overuse characterized by an overwhelming predominance of pro-inflammatory eicosanoids and a relative lack of specialized pro-resolving lipid mediators.
© 2021 Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  eicosanoid; inflammation; lipid mediator; mass spectrometry; resolution; tendon

Mesh:

Substances:

Year:  2021        PMID: 34042218      PMCID: PMC9527947          DOI: 10.1096/fj.202100078R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.834


  103 in total

1.  An experimental study of healing of the partially severed flexor tendon in chickens.

Authors:  H J Kang; B M Park; S B Hahn; E S Kang
Journal:  Yonsei Med J       Date:  1990-09       Impact factor: 2.759

2.  Lipid metabolism in cultured cells. Synthesis of vasoactive thromboxane A2 from [14C]arachidonic acid culture lung fibroblasts.

Authors:  R W Bryant; S J Feinmark; A N Makheja; J M Bailey
Journal:  J Biol Chem       Date:  1978-11-25       Impact factor: 5.157

3.  Nonsteroidal anti-inflammatory drug reduces neutrophil and macrophage accumulation but does not improve tendon regeneration.

Authors:  David Marsolais; Claude H Côté; Jérôme Frenette
Journal:  Lab Invest       Date:  2003-07       Impact factor: 5.662

4.  Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2.

Authors:  Ravindra Rajakariar; Mark Hilliard; Toby Lawrence; Seema Trivedi; Paul Colville-Nash; Geoff Bellingan; Desmond Fitzgerald; Muhammad M Yaqoob; Derek W Gilroy
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-05       Impact factor: 11.205

5.  On the formation and effects of thromboxane A2 in human platelets.

Authors:  J Svensson; M Hamberg; B Samuelsson
Journal:  Acta Physiol Scand       Date:  1976-11

6.  Cyclo-oxygenase-2 mediated prostaglandin release regulates blood flow in connective tissue during mechanical loading in humans.

Authors:  H Langberg; R Boushel; D Skovgaard; N Risum; M Kjaer
Journal:  J Physiol       Date:  2003-06-17       Impact factor: 5.182

7.  Serum and tissue cytokines and chemokines increase with repetitive upper extremity tasks.

Authors:  Mary F Barbe; Melanie B Elliott; Samir M Abdelmagid; Mamta Amin; Steven N Popoff; Fayez F Safadi; Ann E Barr
Journal:  J Orthop Res       Date:  2008-10       Impact factor: 3.494

8.  Macrophage sub-populations and the lipoxin A4 receptor implicate active inflammation during equine tendon repair.

Authors:  Stephanie Georgina Dakin; Dirk Werling; Andrew Hibbert; Dilkush Robert Ephrem Abayasekara; Natalie Jayne Young; Roger Kenneth Whealands Smith; Jayesh Dudhia
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

9.  Increased mast cell numbers in a calcaneal tendon overuse model.

Authors:  J Pingel; J Wienecke; M Kongsgaard; H Behzad; T Abraham; H Langberg; A Scott
Journal:  Scand J Med Sci Sports       Date:  2013-07-25       Impact factor: 4.221

Review 10.  Resolving an inflammatory concept: the importance of inflammation and resolution in tendinopathy.

Authors:  Stephanie G Dakin; Jayesh Dudhia; Roger K W Smith
Journal:  Vet Immunol Immunopathol       Date:  2014-01-31       Impact factor: 2.046

View more
  3 in total

Review 1.  Innate and adaptive immune system cells implicated in tendon healing and disease.

Authors:  G Crosio; A H Huang
Journal:  Eur Cell Mater       Date:  2022-02-18       Impact factor: 4.325

Review 2.  E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition.

Authors:  Charles N Serhan; Stephania Libreros; Robert Nshimiyimana
Journal:  Semin Immunol       Date:  2022-02-16       Impact factor: 11.130

Review 3.  Current knowledge of the implication of lipid mediators in psoriasis.

Authors:  Mélissa Simard; Sophie Morin; Zainab Ridha; Roxane Pouliot
Journal:  Front Immunol       Date:  2022-08-26       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.